The existence of hyperglycemic glycogenolytic factor in the pancreas and the gastric fundus was first reported by Sutherland et al.(1948 and 1949) . Thereafter the existence of glucagon-like materials in the stomach and the small intestine of several species was confirmed immunologically by Unger et al.(1961 and 1966) . Later on, cells to secrete glucagon-like immunoreactive materials (GLI) have been domonstrated in the canine stomach and intestine (Polak et al., 1971) .
Although the biological activity of GLI in the gastrointestinal tract was still a matter of speculation, controversy continued as to whether the intestinal GLI possesses the insulinogenic activity (Buchanan et al., 1969; Moody et al., 1970; Gutman et al., 1973; Murphy et al., 1973; Tanaka et al., 1975b; Ohneda et al., 1976) . Conflicting results regarding this matter were partly due to a difference in the purity of the material employed and the system to study. Therefore, a further investigation into this matter using the purified material in a more sensitive system seems to be worthwhile.
Furthermore, recent reports by Matsuyama and Foa (1974) , Vranic et al.(1974) and Sasaki et al.(1975) suggest the presence of glucagon immunoreactivity, which reacted with antibody specific for pancreatic glucagon, in the gastrointestinal tract, especially abundant in the gastric fundus (Matsuyama et al., 1977) . The biological activities of this material were reported to be close to those of pancreatic glucagon, as far as glycogenolytic and adenylate cyclase stimulating activities were concerned (Sasaki et al., 1975) . However, no information regarding the insulinogenic activity of the material was available.
In order to clarify these points, the insulin-releasing activity of the gastrointestinal GLI purified by affinity chromatography was studied in the rat pancreas perfusion system. . The two antiglucagon sera were employed, namely AGS1W which reacted with both GLI and pancreatic glucagon, the other AGS 18 that was specific for pancreatic glucagon.
Results
Glucagon contents of the extracts .from the pancreas and the gastrointestinal tract Total glucagon-like immunoreactivity and glucagon immunoreactivity were measured using nonspecific antibody (AGS 10) and pancreas-specific antibody (AGS18), respectively. As shown in Table 1 , there was no difference between both values in the extract from the pancreas (EX-P). In the crude fundic extract (EX-F) and further purified preparation by affinity chromato graphy (EG-F), glucagon immunoreactivity was about half of total glucagon-like immunoreactivity, which was less than those of the small intestine. Glucagon immunoreactivity of the small intestine was 5-13% of total glucagon-like immunoreactivity. By means of affinity chromatography GLIs were purified by 2 to 8 times.
Insulin-releasing activity of pancreatic glucagon and gastrointestinal GLIs in the perfused rat pancreas Table 2 shows the insulin-releasing activity of the test agents. The amount of insulin released was significantly enhanced 7min after the commencement of the perfusion with 100ng/min of PG compared with the perfusion with control solution, which contained 100mg/dl of glucose alone. A significantly elevated insulin release was observed in 5-rein perfusion with 100ng/min of EG-F at 5-, 7-and 10-min points. However, 5-min perfusion with 50ng/min of PG or EG-F yielded no significant increase in insulin output over the control.
No discernible insulin releasing activity was found in EG-S1 and EG-S2 from the small intestine. * total glucagon-like immunoreactivity; measured using non -specific antiglucagon serum (AGS 10) ** glucagon immunoreactivity; measured using specific antiglucagon serum (AGS 18) 
Discussion
The existence of glucagon-like immunoreactive materials (GLI) in the gastrointestinal tract, distributed from the stomach to the rectum, is now a well documented fact. However, the composition of GLI seems to be different in various portions of the alimentary tract. A ratio of glucagon immunoreactivity to total glucagon-like immunoreactivity was 1.07 in the extract of porcine Endocrinol. Japon. December 1977 pancreas (EX-P) by the acid alcohol extraction method, 0.53-0.67 in that of the gastric fundus (EX-F, EG-F), 0.04-0.13 in that of the small intestine (EX-S1, EX-S2, EG-S1, EG-S2). Glucagon immunoreactivity was abundant in the extract of the gastric fundus comparing with that of the small intestine. But total glucagon-like immunoreactivity in the extract of the gastric fundus was less than that of the small intestine. Similar al., 1975) . These findings together with the morphological resemblance between the secretory granules of the pancreatic and fundic A cell in dogs (Sasaki et al., 1975) suggest that the mucosa of the gastric fundus contains the material similar or close to pancreatic glucagon, but the materials extracted from the mucosa of the lower half of the small intestine is different physicochemically from pancreatic glucagon.
In this study, after the extraction of acid alcohol extraction method, the extract of the small intestine was devided into two peaks (EX-S1, EX-S2) by the gel filtration. Furthermore, these substance together with the acid alcohol extract of the gastric fundus (EX-F) were further purified by affinity chromatography, by which GL,Is were puri-170 times per mg protein (Tanaka et al., 1975b) .
Using the rat pancreas perfusion system, the insulin-releasing activity of these purified gastrointestinal GLIB was studied in comparison with that of pancreatic glucagon (PG). The method is more sensitive and more physiological than our previous system in which pancreas pieces were employed (Tanaka et al., 1975b) . EG-F promoted the insulin-releasing activity similarily to PG, but neither EG-S1 nor EG-S2 showed insulinogenic activities. Various enteric hormones have been reported to stimulate insulin release. Therefore, the insulin-releasing activity of EG-F might be attributed to these hormones. However, no measurable amount of secretin and CCK-PZ was found in our materials (Tanaka et al., 1975b) . Furthermore, judging from specificity of affinity chromatography and scarcity of another insulinogenic hormone, GIP, in the gastric fundus, it seems unlikely that the insulin-releasing activity of EG-F might be due to these hormones contaminated in this component. Ohneda et al.(1976) reported the insulinogenic activity of the canine intestinal GLI purified by affinity chromatography. The discrepancy between the results of the present study and Ohneda et al. might be attributed to differences in the method, species and systems to study. The insulinogenic activity of their material is not due to the contaminated glucagon immunoreactivity since they failed to measure the glucagon immunoreactivity in the peak II GLI. Anyway, it is apparent that the extract from the gastric fundus possesses the insulinogenic activity.
However, on the basis of the study on the secretory mechanism of gastric glucagon immunoreactivity in dogs (Blazquez et al., 1976) , it is so far unclear what physiological role the insulinogenic activity of glucagon immunoreactivity plays in man.
